Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Issue 9 (23rd April 2020)

• Record Type: Journal Article
• Authors: Levhar, Nina; Ungar, Bella; Kopylov, Uri; Fudim, Ella; Yavzori, Miri; Picard, Orit; Amariglio, Ninette; Chowers, Yehuda; Shemer-Avni, Yonat; Mao, Ren; Chen, Min-hu; Ye, Ziyin; Eliakim, Rami; Ben-Horin, Shomron
• Is Part Of: Inflammatory bowel diseases. Volume 26:Issue 9(2020)
• Page Start: 1330
• Page End: 1339
• Publication Date: 2020-04-23
• Subjects: Epstein–Barr virus -- inflammatory bowel disease -- biological therapies -- lymphoblastoid cell line; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izaa065
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract : An in vitro model for EBV-associated B-cell lymphoma, yielding clonal B-cell populations with distinct surface markers and telomerase activity, was established. We found that cyclosporine, thiopurines, and anti-TNFs, but not anti-integrin, propagate EBV-driven lymphoblastoid transformation. This model may be useful for exploring IBD-drugs' neoplastic potential. Abstract: Background: Immunomodulators and anti tumor-necrosis-α antibodies (anti-TNFs) have been implicated in increased risk of Epstein–Barr virus (EBV)–driven B-cell lymphoproliferative disorders in inflammatory bowel disease (IBD) patients. However, the underlying mechanisms are poorly understood. Methods: An in-vitro model of lymphoblastoid cell line (LCL) was established by co-incubation of EBV-infected human peripheral blood mononuclear cells (PBMC) with Cyclosporin-A (CSA). After 4 weeks, the resultant LCLs were analyzed by flow cytometry, telomerase activity assay, and next generation sequencing. Subsequently, LCLs were explored in the presence of therapeutic agents for IBD (anti-TNFs, vedolizumab, 6-Mercaptopurine [6MP], methotrexate). Epstein–Barr virus titers were quantitated by real-time polymerase chain reaction. Results: In cultures of PBMC with EBV and CSA, LCLs were characterized as an expanded, long lived population of CD58 + CD23 hi B-cells with high telomerase activity and clonal expansion. Upon addition to the cell cultures, LCL percentages were higher with infliximab (median 19.21%, P = 0.011), adalimumab (median 19.85%, P = 0.003), and early washed-out 6MP (median 30.57%, P = 0.043) compared with PBMC with EBV alone (median 9.61%). However, vedolizumab had no such effect (median 8.97%; P = 0.435). Additionally, LCL expansion was accompanied by increase in intracellular, rather than extracellular, EBV viral copies. Compared with PBMC with EBV alone, high levels of LCL were subsequently observed after triple depletion of NK cells, CD4 + T cells, and CD8 + T cells (median 52.8% vs 16.4%; P = 0.046) but also in cultures depleted solely of CD4 + T cells (median 30.7%, P = 0.046). Conclusions: These results suggest that both anti-TNFs and 6MP, but not vedolizumab, propagate EBV-driven lymphoblastoid transformation in an in vitro model of lymphoma. This model may prove useful for studying mechanisms underlying proneoplastic viral immune interactions of novel drugs in IBD therapy.